0
0 (0%)
Oncotelic Therapeutics, Inc. [MATN]
Source:
Company Overview
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. After the acquisition of Mateon Therapeutics, Inc through a reverse merger in 2019, we realigned the company pipeline to focus on rare pediatric cancers.
| Country | United States |
| Headquarters | aguora hills, california |
| Phone Number | 650-635-7000 |
| Industry | manufacturing |
| CEO | Vuong Trieu |
| Website | www.oncotelic.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-3.6 |
| Net Income | |
| Net Cash | $-0.1 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | |
| Profit as % of Stockholder Equity |
Management Effectiveness
| Return on Equity | -57.9% |
| Return on Assets | -17.9% |
| Turnover Ratio | |
| EBITA | $-3.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $26.7 |
| Total Liabilities | $19.2 |
| Operating Cash Flow | $-0.7 |
| Investing Cash Flow | |
| Financing Cash Flow | $0.7 |
